MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1

References

• Song HY, Wang Y, Lan H, Zhang YX. Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma. Exp Ther Med. 2018;16(1):53–60. doi:10.3892/etm.2018.617229896227
   PubMed Web of Science ®Google Scholar
• You L, Wang J, Zhang F, et al. Potential four-miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co-expression analysis. Mol Med Rep. 2019;19(1):441–451. doi:10.3892/mmr.2018.966330483731
   PubMed Web of Science ®Google Scholar
• Chang RK, Li X, Mu N, et al. MicroRNA expression profiles in nonepithelial ovarian tumors. Int J Oncol. 2018;52(1):55–66.29138809
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discovery. 2017;16(3):203–222. doi:10.1038/nrd.2016.24628209991
   PubMed Web of Science ®Google Scholar
• Wei DM, Dang YW, Feng ZB, et al. Biological effect and mechanism of the miR-23b-3p/ANXA2 axis in pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 2018;50(3):823–840. doi:10.1159/00049446830355917
   PubMedGoogle Scholar
• D‘Angelo B, Benedetti E, Cimini A, Giordano A. MicroRNAs: a puzzling tool in cancer diagnostics and therapy. Anticancer Res. 2016;36(11):5571–5575. doi:10.21873/anticanres.1114227793880
   PubMed Web of Science ®Google Scholar
• Huang J, Liu J, Chen-Xiao K, et al. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer. Biomarker res. 2016;4:20. doi:10.1186/s40364-016-0074-3
   PubMedGoogle Scholar
• Cheng Q, Han LH, Zhao HJ, Li H, Li JB. Abnormal alterations of miR-1 and miR-214 are associated with clinicopathological features and prognosis of patients with PDAC. Oncol Lett. 2017;14(4):4605–4612. doi:10.3892/ol.2017.681929085459
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. Rna. 2003;9(2):175–179.12554859
   PubMed Web of Science ®Google Scholar
• Fan Q, Hu X, Zhang H, et al. MiR-193a-3p is an important tumour suppressor in lung cancer and directly targets KRAS. Cell Physiol Biochem. 2017;44(4):1311–1324. doi:10.1159/00048549129183007
   PubMedGoogle Scholar
• Deng W, Yan M, Yu T, et al. Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer. Cell Physiol Biochem. 2015;35(5):1677–1688. doi:10.1159/00037398125833338
   PubMedGoogle Scholar
• Lin M, Duan B, Hu J, et al. Decreased expression of miR-193a-3p is associated with poor prognosis in colorectal cancer. Oncol Lett. 2017;14(1):1061–1067. doi:10.3892/ol.2017.626628693274
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zeng L, Chen Y, et al. Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016;2016:8962321. doi:10.1155/2016/896232126941789
   PubMed Web of Science ®Google Scholar
• Morgado AL, Rodrigues CM, Sola S. MicroRNA-145 regulates neural stem cell differentiation through the Sox2-Lin28/let-7 signaling pathway. Stem Cells. 2016;34(5):1386–1395. doi:10.1002/stem.230926849971
   PubMed Web of Science ®Google Scholar
• Ghosh A, Dasgupta D, Ghosh A, et al. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 2017;8(3):e2706. doi:10.1038/cddis.2017.12328358369
   PubMed Web of Science ®Google Scholar
• Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA therapeutics in cancer - An emerging concept. EBioMedicine. 2016;12:34–42. doi:10.1016/j.ebiom.2016.09.01727720213
   PubMed Web of Science ®Google Scholar
• Takahashi H, Takahashi M, Ohnuma S, et al. microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer. 2017;17(1):723. doi:10.1186/s12885-017-3739-x29115941
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren F, Luo Y, Rong M, Chen G, Dang Y. Down-regulation of MiR-193a-3p dictates deterioration of HCC: a clinical real-time qRT-PCR study. Med sci monit. 2015;21:2352–2360. doi:10.12659/MSM.89407726263159
   PubMed Web of Science ®Google Scholar
• Seviour EG, Sehgal V, Mishra D, et al. Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene. 2017;36(10):1339–1350. doi:10.1038/onc.2016.30827669434
   PubMed Web of Science ®Google Scholar
• Jia L, Gui B, Zheng D, et al. Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration. Prostate. 2017;77(9):1000–1011. doi:10.1002/pros.2335628422308
   PubMed Web of Science ®Google Scholar
• Wang ZZ, Yang J, Jiang BH, et al. KIF14 promotes cell proliferation via activation of Akt and is directly targeted by miR-200c in colorectal cancer. Int J Oncol. 2018;53(5):1939–1952. doi:10.3892/ijo.2018.454630226594
   PubMed Web of Science ®Google Scholar
• Gopalan V, Smith RA, Lam AK. Downregulation of microRNA-498 in colorectal cancers and its cellular effects. Exp Cell Res. 2015;330(2):423–428. doi:10.1016/j.yexcr.2014.08.00625128149
   PubMed Web of Science ®Google Scholar
• Mamoori A, Wahab R, Islam F, et al. Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. Hum Pathol. 2018;71:145–156. doi:10.1016/j.humpath.2017.10.02429104111
   PubMed Web of Science ®Google Scholar
• Uhlmann S, Mannsperger H, Zhang JD, et al. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 2012;8:570. doi:10.1038/msb.2011.10022333974
   PubMed Web of Science ®Google Scholar
• Yu M, Liu Z, Liu Y, et al. PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p. FEBS J. 2018;doi:10.1111/febs.14724.
   Web of Science ®Google Scholar
• Jian B, Li Z, Xiao D, He G, Bai L, Yang Q. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol. 2016;37(7):8941–8949. doi:10.1007/s13277-015-4727-x26753960
   PubMed Web of Science ®Google Scholar
• Liu L, Li Y, Liu S, et al. Downregulation of miR-193a-3p inhibits cell growth and migration in renal cell carcinoma by targeting PTEN. Tumour Biol. 2017;39(6):1010428317711951. doi:10.1177/101042831771195128639901
   PubMedGoogle Scholar
• Huang Y, Luo H, Li F, et al. LINC00152 down-regulated miR-193a-3p to enhance MCL1 expression and promote gastric cancer cells proliferation. Biosci Rep. 2018;38:3. doi:10.1042/BSR20171607
   Web of Science ®Google Scholar
• Gao XN, Lin J, Li YH, et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene. 2011;30(31):3416–3428. doi:10.1038/onc.2011.6221399664
   PubMed Web of Science ®Google Scholar
• Liang H, Liu M, Yan X, et al. miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4. J Biol Chem. 2015;290(2):926–940. doi:10.1074/jbc.M114.62140925391651
   PubMed Web of Science ®Google Scholar
• Pan Y, Hu J, Ma J, et al. MiR-193a-3p and miR-224 mediate renal cell carcinoma progression by targeting alpha-2,3-sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway. Mol Carcinog. 2018;57(8):1067–1077. doi:10.1002/mc.2282629667779
   PubMed Web of Science ®Google Scholar
• Li J, Wei J, Mei Z, et al. Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44. Am J Transl Res. 2017;9(1):146–154.28123641
   PubMed Web of Science ®Google Scholar
• Kumari S, Prasad SB, Yadav SS, et al. Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer. Med oncol. 2016;33(5):40. doi:10.1007/s12032-016-0754-827034264
   PubMed Web of Science ®Google Scholar
• Dai J, Wei RJ, Li R, Feng JB, Yu YL, Liu PS. A study of CCND1 with epithelial ovarian cancer cell proliferation and apoptosis. Eur Rev Med Pharmacol Sci. 2016;20(20):4230–4235.27831653
   PubMed Web of Science ®Google Scholar
• Rozengurt E, Sinnett-Smith J, Eibl G. Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival. Signal Transduction Targeted Ther. 2018;3:11. doi:10.1038/s41392-017-0005-2
   PubMed Web of Science ®Google Scholar
• Yan L, Wang Y, Wang ZZ, et al. Cell motility and spreading promoted by CEACAM6 through cyclin D1/CDK4 in human pancreatic carcinoma. Oncol Rep. 2016;35(1):418–426. doi:10.3892/or.2015.433826497080
   PubMed Web of Science ®Google Scholar
• Lee Y, Ko D, Min HJ, et al. TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1. Oncotarget. 2016;7(31):50315–50332. doi:10.18632/oncotarget.1038227385093
   PubMedGoogle Scholar
• Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 1999;59(14):3505–3511.10416617
   PubMed Web of Science ®Google Scholar
• Shi Y, Qian ZR, Zhang S, et al. Cell cycle protein expression in neuroendocrine tumors: association of CDK4/CDK6, CCND1, and phosphorylated retinoblastoma protein with proliferative index. Pancreas. 2017;46(10):1347–1353. doi:10.1097/MPA.000000000000094428991877
   PubMed Web of Science ®Google Scholar
• Vodicka P, Musak L, Vodickova L, et al. Genetic variation of acquired structural chromosomal aberrations. Mutat Res. 2018;836(Pt A):13–21. doi:10.1016/j.mrgentox.2018.05.014
   Google Scholar
• Casimiro MC, Crosariol M, Loro E, et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest. 2012;122(3):833–843. doi:10.1172/JCI6025622307325
   PubMed Web of Science ®Google Scholar
• Jirawatnotai S, Hu Y, Michowski W, et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 2011;474(7350):230–234. doi:10.1038/nature1015521654808
   PubMed Web of Science ®Google Scholar